Analysis of the role of interleukin 6 receptor haplotypes in the regulation of circulating levels of inflammatory biomarkers and risk of coronary heart disease

PloS One
Bruna GiganteUlf de Faire

Abstract

Variants at the interleukin 6 receptor (IL6R) gene regulate inflammation and are associated with risk of coronary heart disease (CHD). The aim of the present study was to investigate the effects of IL6R haplotypes on circulating levels of inflammatory biomarkers and risk of CHD. We performed a discovery analysis in SHEEP, a myocardial infarction (MI) case control study (n = 2,774) and replicated our results in two large, independent European populations, PROCARDIS, a CHD case control study (n = 7,998), and IMPROVE (n = 3,711) a prospective cardiovascular cohort study. Two major haplotype blocks (rs12083537A/G and rs4075015A/T--block 1; and rs8192282G/A, rs4553185T/C, rs8192284A/C, rs4240872T/C and rs7514452T/C--block 2) were identified in the IL6R gene. IL6R haplotype associations with C-reactive protein (CRP), fibrinogen, IL6, soluble IL6R (sIL6R), IL6, IL8 and TNF-α in SHEEP, CRP and fibrinogen in PROCARDIS and CRP in IMPROVE as well as association with risk of MI and CHD, were analyzed by THESIAS. Haplotypes in block 1 were associated neither with circulating inflammatory biomarkers nor with the MI/CHD risk. Haplotypes in block 2 were associated with circulating levels of CRP, in all three study populations, with fibrinogen ...Continue Reading

References

Apr 27, 1996·BMJ : British Medical Journal·J M Bland, D G Altman
Sep 14, 2000·Proceedings of the National Academy of Sciences of the United States of America·C M DrysdaleS B Liggett
Sep 7, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·V MarinG Kaplanski
May 25, 2002·Science·Stacey B GabrielDavid Altshuler
Feb 7, 2004·Molecular Biotechnology·Christian JurinkeDirk van den Boom
Aug 7, 2004·Bioinformatics·J C BarrettM J Daly
Nov 16, 2004·Genetic Epidemiology·Daniel J Schaid
Jan 22, 2005·Annual Review of Medicine·Dana C Crawford, Deborah A Nickerson
Jan 23, 2008·Journal of Cardiovascular Pharmacology·Kersten M SmallStephen B Liggett
May 8, 2009·Nature Reviews. Cardiology·Gayle E McKellarIain B McInnes
Jul 2, 2009·JAMA : the Journal of the American Medical Association·Paul ElliottJaspal S Kooner
Jan 19, 2012·Clinica Chimica Acta; International Journal of Clinical Chemistry·Karin LeanderJohan Högberg
Mar 17, 2012·Lancet·UNKNOWN IL6R Genetics Consortium Emerging Risk Factors CollaborationJohn Danesh
Mar 17, 2012·Lancet·UNKNOWN Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) ConsortiumJuan Pablo Casas
Dec 4, 2012·Nature Genetics·Panos DeloukasNilesh J Samani

❮ Previous
Next ❯

Citations

Oct 18, 2016·BioMed Research International·Veronika GüntherChristel Eckmann-Scholz
Apr 1, 2018·Thoracic Cancer·Zuoqing SongYuxin Wang
Apr 10, 2018·The Journal of Clinical Investigation·Yuichi TamuraChristophe Guignabert
Feb 25, 2017·The International Journal of Cardiovascular Imaging·Lei ZhaoYuhai Yang
Aug 19, 2017·Mammalian Genome : Official Journal of the International Mammalian Genome Society·Lu KouQin Qin
May 16, 2019·Scientific Reports·Julia MorrisRona J Strawbridge

❮ Previous
Next ❯

Methods Mentioned

BETA
dissect
PROCARDIS
genotyping
chips

Software Mentioned

THESIAS
Haploview
PROCARDIS
IMPROVE

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.